Additional Information

Description

Entyvio® (vedolizumab) 300 mg injection is a biologic medication indicated for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults. It is designed to reduce inflammation in the gastrointestinal tract by targeting and inhibiting integrin a4ß7. This action prevents the migration of lymphocytes into inflamed gastrointestinal tissues, thereby reducing inflammation and promoting healing of the gut lining.

Vedolizumab is administered intravenously and must be reconstituted and diluted prior to use. The treatment regimen typically involves initial doses at 0, 2, and 6 weeks, followed by maintenance doses every 8 weeks. The dosing schedule may be adjusted based on the patient’s response to therapy.

Before use, Entyvio® should be refrigerated between 2ºC to 8ºC (36ºF to 46ºF) and retained in its original packaging to protect it from light. Common side effects include headache, fatigue, nausea, and upper respiratory tract infections. Serious adverse effects may include infections, liver damage, and allergic reactions.